Project Overview

P_ERP012611

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Visibility: Public
Publication: Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome Link
 Journal: Gut Microbes
Source: NA
Sample Number: 175

Samples in this project
  

SampleID Type Habitat Year Sequence type MNS1 MAS2
S_ERP012611.ERR1051053 Gut Feces 2012 16S - -
S_ERP012611.ERR1051054 Gut Feces 2012 16S - -
S_ERP012611.ERR1051055 Gut Feces 2012 16S - -
S_ERP012611.ERR1051056 Gut Feces 2012 16S - -
S_ERP012611.ERR1051057 Gut Feces 2012 16S - -
S_ERP012611.ERR1051058 Gut Feces 2012 16S - -
S_ERP012611.ERR1051059 Gut Feces 2012 16S - -
S_ERP012611.ERR1051060 Gut Feces 2012 16S - -
S_ERP012611.ERR1051061 Gut Feces 2012 16S - -
S_ERP012611.ERR1051062 Gut Feces 2012 16S - -
S_ERP012611.ERR1051063 Gut Feces 2012 16S - -
S_ERP012611.ERR1051064 Gut Feces 2012 16S - -
S_ERP012611.ERR1051065 Gut Feces 2012 16S - -
S_ERP012611.ERR1051066 Gut Feces 2012 16S - -
S_ERP012611.ERR1051067 Gut Feces 2012 16S - -
S_ERP012611.ERR1051068 Gut Feces 2012 16S - -
S_ERP012611.ERR1051069 Gut Feces 2012 16S - -
S_ERP012611.ERR1051070 Gut Feces 2012 16S - -
S_ERP012611.ERR1051071 Gut Feces 2012 16S - -
S_ERP012611.ERR1051072 Gut Feces 2012 16S - -

1MNS (Microbiome Novelty Score): < 0.12: Non-novel; 0.12-0.2: Novel; > 0.2: Very novel; -: NA for samples before 2010

2MAS (Microbiome Attention Score): < 10: Low-attention; ≥ 10: High-attention; -: NA for samples before 2010